Here you will find financial information about InDex and can subscribe to press releases and reports. If you have questions, please contact our IR contact.
- InDex Pharmaceuticals Holding AB (publ) interim report January – September 201819 November 2018
- InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2019 Annual General Meeting06 November 2018
- InDex Pharmaceuticals carries out a directed share issue of approximately SEK 37.5 million23 October 2018
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.Learn more